SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
As a part of the NMD4C’s clinical research work pillar, we are supporting the development and training on validated NMD outcome measures. Considering the evolving therapeutic landscape of SMA and the need for high-quality real-world data, convening clinicians to discuss and train on nationally agreed-upon outcome measures (OM) will enhance our capacity to uncover significant disease trajectory patterns and therapy responses.
We are pleased to share an opportunity for physiotherapists and occupational therapists to attend our first training session of this kind for outcome measures in Spinal muscular atrophy (SMA):
Standardized Outcome Measure training in SMA
Saturday, March 23, 2024 | Hôtel Château Laurier Québec: 1220, Place George-V Ouest, Québec, QC
To complement this training session, we will host an English-language training on standardizing assessment practices in SMA outcome measures later in 2024, which will include the learnings from the March training session in Quebec. We will reach out to share more information on this English-language training session when details are available.
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.
MICYRN Secures $20 Million Grant from CIHR for a Pediatric Rare Disease Clinical Trials and Treatment Network
The NMD4C are excited to share that MICYRN’s success in securing a $20 million grant from CIHR Institute of Genetics to support the development and execution of RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network.